| Placebo (n = 514) | Tanezumab 2.5 mg (n = 514) | Tanezumab 5 mg (n = 517) |
---|---|---|---|
Non-work activities | |||
 Percent activity impairment | |||
  n | 448 | 476 | 482 |
  LS mean (SE) change from baseline | −23.49 (1.22) | − 29.41 (1.20) | − 29.45 (1.19) |
  Difference in LS means (95% CI) |  | −5.92 (−8.87, − 2.98) | −5.96 (− 8.89, − 3.02) |
  p value |  | < 0.0001 | < 0.0001 |
Work productivity | |||
 Percent work time missed | |||
  n | 127 | 142 | 126 |
  LS mean (SE) change from baseline | −0.20 (1.19) | −0.86 (1.16) | − 3.60 (1.21) |
  Difference in LS means (95% CI) |  | −0.66 (−3.63, 2.32) | − 3.40 (− 6.47, − 0.34) |
  p value |  | 0.6637 | 0.0294 |
 Percent impairment while working | |||
  n | 124 | 140 | 125 |
  LS mean (SE) change from baseline | −18.59 (2.29) | −25.94 (2.22) | −26.46 (2.31) |
  Difference in LS means (95% CI) |  | −7.34 (−13.01, − 1.68) | −7.87 (− 13.71, − 2.03) |
  p value |  | 0.0112 | 0.0084 |
 Percent overall work impairment | |||
  n | 124 | 140 | 125 |
  LS mean (SE) change from baseline | −19.12 (2.33) | −26.56 (2.26) | −27.49 (2.36) |
  Difference in LS means (95% CI) |  | −7.44 (−13.22, − 1.67) | −8.37 (−14.32, − 2.42) |
  p value |  | 0.0116 | 0.0060 |